Ph.D. in Pharmaceutical Sciences or related areas. OR M.Pharm. or equivalent in Pharmaceutics or related areas, with 3 years of experience in relevant area.
EMBO provides grants for host institutions in EMBC Member States to issue employment contracts to EMBO Fellows. Fellows working in other countries than EMBC Member States will receive a stipend.
Masters, Integrated Masters in Natural or Agricultural or Pharmaceutical Sciences, MVSc, Animal Sciences. Or Bachelors degree in Engineering or Technology or Medicine from a recognized University or equivalent.
First class in relevant Post Graduate Degree with three years experience or PhD Degree. Experience in fabricating and characterization of ocular drug delivery devices.
M.Sc in Chemistry from a recognised University or equivalent. Experience in the field of natural product chemistry and analytical chemistry of plant secondary metabolites.
M.Pharm, B.Pharm, M.Sc ; 2 to 8 Years of Experience in Analytical Compliance, Cleaning Sampling, RA Co-Ordination, Process Validation, QMS, Training Co-Ordination.
Perform line clearance, in-process checks, and timely documentation. Responsibilities also include analytical QA oversight, GMP monitoring. APQR and CVP execution, and maintaining data integrity and compliance across all functions.
Post Graduate degree such as M. Sc. Biotechnology, Microbiology, Medical Biotechnology or M. Tech. Biotechnology or any allied area of science with 3 years of post-qualification research experience or Ph.D.
Line clearance activity for Washing, Filling, Sealing, Visual inspection. Performing Environmental monitoring activity in Grade A, B, C and D clean room area. In process activity.
As AstraZeneca’s multibillion-dollar heart drug ticagrelor (marketed as Brilinta in the U.S. and Brilique in Europe) prepares to go off-patent, a fresh investigation by The BMJ has raised troubling concerns about the integrity of the trials that supported its approval. The antiplatelet medication has been widely used for over a decade to treat patients with acute coronary syndrome, but the evidence base it rests on is now under question.